MX2023004439A - Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina. - Google Patents

Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina.

Info

Publication number
MX2023004439A
MX2023004439A MX2023004439A MX2023004439A MX2023004439A MX 2023004439 A MX2023004439 A MX 2023004439A MX 2023004439 A MX2023004439 A MX 2023004439A MX 2023004439 A MX2023004439 A MX 2023004439A MX 2023004439 A MX2023004439 A MX 2023004439A
Authority
MX
Mexico
Prior art keywords
receptor
alpha
canine
canine interleukin
caninized antibodies
Prior art date
Application number
MX2023004439A
Other languages
English (en)
Spanish (es)
Inventor
Mohamad Morsey
Yuanzheng Zhang
Anasuya Saha
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2023004439A publication Critical patent/MX2023004439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023004439A 2020-10-15 2021-10-14 Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina. MX2023004439A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202063092296P 2020-10-15 2020-10-15
US202063092294P 2020-10-15 2020-10-15
US202063127184P 2020-12-18 2020-12-18
US202163235257P 2021-08-20 2021-08-20
US202163235258P 2021-08-20 2021-08-20
PCT/EP2021/078386 WO2022079139A1 (en) 2020-10-15 2021-10-14 Caninized antibodies to canine interleukin-31 receptor alpha

Publications (1)

Publication Number Publication Date
MX2023004439A true MX2023004439A (es) 2023-05-08

Family

ID=78302732

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023004439A MX2023004439A (es) 2020-10-15 2021-10-14 Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina.
MX2023004438A MX2023004438A (es) 2020-10-15 2021-10-14 Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023004438A MX2023004438A (es) 2020-10-15 2021-10-14 Anticuerpos de rata caninizados para el receptor alfa de interleucina-31 canino.

Country Status (8)

Country Link
US (2) US20240002518A1 (https=)
EP (2) EP4229084A1 (https=)
JP (2) JP2023545182A (https=)
CN (1) CN116348488A (https=)
AU (2) AU2021359068A1 (https=)
CA (2) CA3194384A1 (https=)
MX (2) MX2023004439A (https=)
WO (2) WO2022079139A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112491WA (en) * 2019-07-31 2021-12-30 Hoffmann La Roche Antibodies binding to gprc5d
AU2021359068A1 (en) * 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
EP4642795A2 (en) 2022-12-27 2025-11-05 Invetx, Inc. Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use
AU2024210302A1 (en) 2023-01-20 2025-09-04 Invetx, Inc. Bispecific binding agents for use in companion animals
CN120865402A (zh) * 2023-11-27 2025-10-31 宁波贝安生物科技有限公司 抗il-31的抗体及其用途
WO2026032397A1 (en) * 2024-08-09 2026-02-12 Zai Lab (Shanghai) Co., Ltd. Binding molecules with an interleukin-31 receptor subunit alpha-antigen-binding domain and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
JP4884570B2 (ja) 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6701079B2 (ja) 2013-12-20 2020-05-27 インターベット インターナショナル ベー． フェー． ヒトｐｄ−１に対するイヌ化マウス抗体
AU2016239858B2 (en) 2015-04-02 2021-07-01 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
US11091556B2 (en) * 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
AU2017376398B2 (en) 2016-12-14 2021-07-15 Intervet International B.V. Aminopyrazoles as selective janus kinase inhibitors
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
US11236157B2 (en) * 2019-01-28 2022-02-01 Galderma Holding SA Treatment of skin lesions and pruritus in prurigo nodularis patients
CN110563844A (zh) 2019-09-04 2019-12-13 华中农业大学 一种抗犬白介素31受体的多克隆抗体及其应用
AU2021359068A1 (en) 2020-10-15 2023-06-15 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha

Also Published As

Publication number Publication date
AU2021359068A1 (en) 2023-06-15
CN116348488A (zh) 2023-06-27
EP4229083A1 (en) 2023-08-23
CA3194384A1 (en) 2022-04-21
AU2021359068A8 (en) 2023-06-22
US12577310B2 (en) 2026-03-17
MX2023004438A (es) 2023-05-08
AU2021360208A1 (en) 2023-04-27
JP2023545183A (ja) 2023-10-26
AU2021360208A9 (en) 2025-03-27
JP2023545182A (ja) 2023-10-26
WO2022079139A1 (en) 2022-04-21
WO2022079138A1 (en) 2022-04-21
US20240002518A1 (en) 2024-01-04
CA3194457A1 (en) 2022-04-21
US20230391879A1 (en) 2023-12-07
AU2021359068A9 (en) 2024-06-06
EP4229084A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
MX2023004439A (es) Anticuerpos caninizados contra el receptor alfa de la interleucina-31 canina.
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
PH12020552138A1 (en) Bcma chimeric antigen receptors and uses thereof
MX2016002150A (es) Anticuerpos anti-prlr y usos de los mismos.
CR20200467A (es) Agentes anticuerpos anti-cd25
MA39061A1 (fr) Modulateurs d'aplnr et leurs utilisations
MY187975A (en) Antigen-binding proteins that activate the leptin receptor
MY159787A (en) High affinity antibodies to human il-6 receptor
MX2022007677A (es) Anticuerpos para receptor alfa de interleucina-4 canino.
SG196839A1 (en) Antibodies against fcrn and use thereof
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
MX2024007090A (es) Anticuerpos caninizados para el receptor alfa ii de interleucina-31 canino.
MX2022014995A (es) Metodos de tratamiento de la nefropatia por iga con un anticuerpo de union a april.
IL288607A (en) High affinity anti-cd3 antibodies and methods for their creation and use
ZA202309516B (en) Anti-ccr8 antibodies
WO2022040088A3 (en) Cd45 binding molecules and methods of use
ZA201807816B (en) Anti-il-22r antibodies
JOP20240042A1 (ar) أجسام مضادة لمستقبلات الترانسفيرين واستخداماتها
EA202192413A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ
MX2022013956A (es) Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion especificas de cd70.
MX2020005495A (es) Anticuerpo anti-vista y uso del mismo.
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
ZA202401100B (en) Human interleukin-4 receptor alpha antibodies
MX2022016494A (es) Anticuerpos anti-il13ra2.